Please assess the completion status of the following clinical trial:

Trial Title: Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recently diagnosed type 2 diabetes (within 3 years) on diet or IGT~* Fasting triglyceride levels \>140 and \< 400 mg/dl and values varying less than 35% between two screening measurements~* Normal liver function tests and white blood cell count~Exclusion Criteria:~* Type 2 Diabetes for \> 3 years or HbA1c ≥ 7.5~* Known or suspected Type 1 Diabetes~* Any diabetes medications in the past 3 weeks, TZD in the prior 3 months or prior regular use of insulin~* Creatinine \> 2.0 mg/dl or other evidence of active kidney disease~* Hepatic enzyme elevation \> 2x normal~* Known Nonalcoholic Fatty Liver Disease~* Malabsorption of fat or other nutrients, severe lactose intolerance or other significant gastrointestinal or pancreatic problems~* Recent history of nausea or vomiting~* Acute bacterial or viral illness or evidence of other active infection in the past 4 weeks~* A prior cardiovascular event, stable or unstable angina or other major illness in the past 6 months~* Current regular use of anti-inflammatory medications or antioxidants, including over the counter medications and high dose salicylates (\>1 g/day)~* Any lipid lowering therapy in the prior 3 weeks other than a statin medication. Subjects receiving a statin medication must be on a stable dose for at least 2 months prior to participation.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).